Cerebrotendinous xanthomatosis presenting with infantile spasms and intellectual disability

JIMD Reports

Volumn 35, Issue , 2017, Pages 1-5

  Larson, Austin ^a,b   Weisfeld Adams, James D ^a   Benke, Tim A ^c   Bonnen, Penelope E ^d  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cataracts; Cerebrotendinous xanthomatosis; Developmental delay; Infantile spasms; Intellectual disability

Indexed keywords

EID: 85031899430     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2016_16     Document Type: Chapter

References (20)

1. Appadurai V, DeBarber A, Chiang P-W et al (2015) Apparent under-diagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab 116: 298–304
2. Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876. pubs.rsna.org
3. Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147
4. Berginer VM, Salen G, Patel SB (2015) Cerebrotendinous xanthomatosis. In: Rosenberg RN, Pascual JM (eds) Rosenberg’s molecular and genetic basis of neurological and psychiatric disease. Academic Press, Elsevier, London, pp. 589–598
5. Clayton PT, Verrips A, Sistermans E et al (2002) Mutations in the sterol 27-hydoxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 25:501–513
6. Cruysberg JR, Wevers RA, van Engelen BG et al (1995) Ocular and systemic manifestations of cerebrotendinous xanthomatosis. Am J Ophthalmol 120:597–604
7. Degos B, Nadjar Y, Amador M et al (2016) Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis 11:41
8. Gupta RP, Patrick K, Bell NH (2007) Mutational analysis of CYP27A1: assessment of 27-hydroxylation of cholesterol and 25-hydroxylation of vitamin D. Metabolism 56:1248–1255
9. Huidekoper HH, Vaz FM, Verrips A, Bosch AM (2016) Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment. Eur J Pediatr 175:143–146
10. Kauffman MA, Gonzalez-Morón D, Consalvo D, Kochen S (2012) Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. Am J Med Sci 343:332–333
11. Michaud JL, Lachance M, Hamdan FF et al (2014) The genetic landscape of infantile spasms. Hum Mol Genet 23:4846–4858
12. Mignarri A, Gallus GN, Dotti MT, Federico A (2014) A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis 37:421–429
13. Mignarri A, Magni A, Del Puppo M et al (2016) Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J Inherit Metab Dis 39(1):75–83. doi:10.1007/s10545-015-9873-1, Epub 2015 Jul 8
14. Paciorkowski AR, Thio LL, Rosenfeld JA et al (2011) Copy number variants and infantile spasms: evidence for abnormalities in ventral forebrain development and pathways of synaptic function. Eur J Hum Genet 19:1238–1245
15. Panzenboeck U, Andersson U, Hansson M et al (2007) On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J Lipid Res 48: 1167–1174
16. Pedroso JL, Pinto WB, Souza PV et al (2012) Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav 24:380–381
17. Reshef A, Meiner V, Berginer VM, Leitersdorf E (1994) Molecular genetics of cerebrotendinous xanthomatosis in Jews of north African origin. J Lipid Res 35:478–483
18. Van Heijst A, Verrips A, Wevers RA et al (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316
19. Verrips A, Hoefsloot LH, Steenbergen GC et al (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123(Pt 5):908–919
20. Yahalom G, Tsabari R, Molshatzki N, et al (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83. journals.lww.com